USPTO serial 79207058
MIRXES
Reviewed by CopyMark Law Group
Reg. 5440477Status 739Registered
- Filing date
- Status date
- Registration date
- Apr 10, 2018
- Examiner
- LEIPZIG, MARC J
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with MIRXES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joseph Chu
Joseph Chu JCIP155 N Lake Avenue, Suite 800Century SquarePasadena, CA 91101Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical and veterinary purposes; diagnostic agents for medical and veterinary purposes, namely, reactants for medical and veterinary diagnosis; medical diagnostic kit consisting primarily of diagnostic preparations for medical use; diagnostic products for medical purposes, namely, blood test kits consisting primarily of medical diagnostic reagents and test strips for the diagnosis of cancer, cardiovascular disorders, metabolic disorders, neurological disorders and immune disorders; biological indicators for medical diagnosis; veterinary diagnostic reagents; medical diagnostic kit consisting primarily of diagnostic reagents for medical and veterinary purposes for conducting Real Time Polymerase Chain Reaction assays (RT-PCR); chemical reagents for medical or veterinary laboratory purposes; medical and veterinary diagnostic reagents for use in testing the presence of cancer, cardiovascular disorders, metabolic disorders, neurological disorders and immune disorders; pharmaceutical preparations for the treatment of disorders of the metabolic system; medical diagnostic reagents for testing of body fluids; stem cells for medical and veterinary purposes; substances for use in genetic probe assay kits, namely, medical diagnostic reagents, for medical use; diagnostic preparations for medical purposes; biochemical preparations for diagnostic use, namely, for use in testing the presence of cancer, cardiovascular disorders, metabolic disorders, neurological disorders and immune disorders; products for medical diagnosis, namely, blood test kits consisting primarily of medical diagnostic reagents and test strips for diagnosis of cancer, cardiovascular disorders, metabolic disorders, neurological disorders and immune disorders; diagnostic agents for medical use; test reagents for medical diagnostic use; diagnostic biomarker reagents for medical purposes; chemical preparations for medical diagnostic purposes; chemical preparations for medical use in DNA analysis; chemical products in the nature of biomarker discovery solutions for medical diagnosis and analysis; biological preparations for medical use in the analysis of cell cultures; medical diagnostic preparations for detecting genetic predispositions for medical purposes; medical diagnostic reagents for analytical purposes; synthetic deoxyribonucleic acid and synthetic ribonucleic acid for medical use; nucleic acid amplification reagents for medical use | ACTIVE | — |
| 042 | Research and development of technology in the field of microRNA, DNA, molecular biology, biochemistry, genetic engineering, polymerase chain reactions, agriculture, botany and horticulture; research and development of new products; research and development in the field of microRNA; research and development in the field of microorganisms and cells; research relating to molecular sciences; provision of information and data relating to medical and veterinary research and development; research and development services in the field of antibody technology; research and development services in the field of cell therapy; research and development services in the field of in-vitro fertilization; research and development services in the field of neurodegenerative diseases; research and development services in the field of gene expression systems; chemical laboratory services; laboratory testing of blood, biofluids, stem cells, cancer cells, plants, plant seeds and crop seeds for research; contract scientific research in the field of molecular sciences; laboratory analysis in the field of microRNA, DNA, molecular biology, biochemistry, genetic engineering, polymerase chain reactions, agriculture, botany and horticulture for research; laboratory research in the field of microRNA, DNA, molecular biology, biochemistry, genetic engineering, polymerase chain reactions, agriculture, botany and horticulture; conducting scientific research in the nature of clinical trials for others in the field of microRNA, DNA, molecular biology, biochemistry, genetic engineering polymerase chain reactions, agriculture, botany and horticulture; laboratory research services relating to the field of microRNA technology; biological and biochemical analysis; bioinformatics analysis; veterinary laboratory services; scientific research and development; scientific analysis in the field of molecular biology; scientific research for medical purposes in the area of cancerous diseases; scientific structural and functional analysis of genomes; agricultural research services; scientific laboratory services for agricultural research; biotechnological research relating to agriculture; scientific research in the field of stem cell research; development and testing of computing methods, algorithms computer networks and computer software for others; providing testing and preparation services in relation to immunohistological samples for analysis in research laboratories; technical diagnostic testing services in the field of microRNA, DNA, molecular biology, biochemistry, genetic engineering, polymerase chain reactions, agriculture, botany and horticulture for research; genetic testing for scientific research purposes; medical research services; biomedical research services; biochemistry research services; DNA testing services for scientific research purposes; DNA screening for scientific research purposes; pharmaceutical research services; biological research and analysis; biochemical research and analysis; scientific laboratory services; scientific and technical analysis in the field of microRNA, DNA, molecular biology, biochemistry, genetic engineering, polymerase chain reactions, agriculture, botany and horticulture; technical data analysis services in the field of microRNA, DNA, molecular biology, biochemistry, genetic engineering, polymerase chain reactions, agriculture, botany and horticulture for research; medical research services featuring the analysis of tissues; environmental testing and inspection services; technical consultancy in the field of environmental science; research in the field of environmental protection; providing advisory and consultation services in connection with product testing | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 3, 2024 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Oct 3, 2024 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Sep 30, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 31, 2024 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Apr 10, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Sep 17, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 23, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 23, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 23, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 23, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 24, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 27, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 27, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 10, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 10, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 23, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 23, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 19, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 3, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 3, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 3, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 18, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 18, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 18, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 18, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 18, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 9, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 9, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 9, 2017 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 9, 2017 | ALIE | ASSIGNED TO LIE | — |
| Dec 6, 2017 | ALIE | ASSIGNED TO LIE | — |
| Nov 28, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 23, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 24, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 2, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 2, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 18, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 17, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 17, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 13, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| May 13, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 11, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |